Saturday, July 20, 2024 8:08:22 AM
Tommy its not HYPE, its called a PH 3 data release
IF you have been investing in bios, you should know that
clinical trials try to 'prove' something. And if they are successful,
likely to lead to an increase in revenues (note, not every development
is actually a revenue generator, ask Sony and their BETA development vs
VHS)
So out of curiosity, why are you claiming this is all 'hype'??
The PH 3 data will answer the first question of, does it work or not.
The next few questions if the data is good, will be, will it 'sell' and how
much (volume of sales), and for 'how much' (profits). While I dislike reverse
splits when they are done at the wrong time, one positive is, the severely reduced
share count can make things a bit more exciting (less shares to spread any profits against)
going forward..
and a disclaimer: yes, I held no shares when the r/split occurred, and didn't start buying
until the share price had fallen below $5/sh.
Here's hoping the PH 3 data is good, especially for those that could benefit from its development
They already have a life changing event in progress, and anything that makes it easier to deal with,
you have to hope for their sake, it happens
IF you have been investing in bios, you should know that
clinical trials try to 'prove' something. And if they are successful,
likely to lead to an increase in revenues (note, not every development
is actually a revenue generator, ask Sony and their BETA development vs
VHS)
So out of curiosity, why are you claiming this is all 'hype'??
The PH 3 data will answer the first question of, does it work or not.
The next few questions if the data is good, will be, will it 'sell' and how
much (volume of sales), and for 'how much' (profits). While I dislike reverse
splits when they are done at the wrong time, one positive is, the severely reduced
share count can make things a bit more exciting (less shares to spread any profits against)
going forward..
and a disclaimer: yes, I held no shares when the r/split occurred, and didn't start buying
until the share price had fallen below $5/sh.
Here's hoping the PH 3 data is good, especially for those that could benefit from its development
They already have a life changing event in progress, and anything that makes it easier to deal with,
you have to hope for their sake, it happens
Recent JAGX News
- Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs • ACCESS Newswire • 04/13/2026 12:30:00 PM
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:50 PM
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs • ACCESS Newswire • 04/08/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:22 PM
- Jaguar Health Reports 2025 Financials • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/07/2026 10:10:28 AM
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress • ACCESS Newswire • 04/02/2026 01:00:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:19:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 09:06:18 PM
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 03/18/2026 01:00:00 PM
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression • ACCESS Newswire • 03/16/2026 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/13/2026 08:59:50 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts • ACCESS Newswire • 03/11/2026 01:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:05:16 PM
- Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants • ACCESS Newswire • 03/09/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 02:05:51 PM
- Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 • ACCESS Newswire • 03/03/2026 02:00:00 PM
- Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend • ACCESS Newswire • 03/02/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:01:37 PM
- Jaguar Health Announces a Special One-time Stock Dividend • ACCESS Newswire • 02/18/2026 02:00:00 PM
